Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: An economic analysis

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Zhu, Jun ^a   Li, Te ^a   Wang, Xiaohui ^b   Ye, Ming ^c   Cai, Jian ^d   Xu, Yuejuan ^e   Wu, Bin ^c  

^a SHANGHAI CHEST HOSPITAL   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d YANGZHOU UNIVERSITY   (China)

^e SOUTHEAST UNIVERSITY   (China)

Author keywords

Cost effectiveness; EGFR mutation; Gefitinib maintenance treatment; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PEMETREXED;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; ECONOMIC EVALUATION; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; DRUG COSTS; HUMANS; INDIVIDUALIZED MEDICINE; LIFE EXPECTANCY; LUNG NEOPLASMS; MARKOV CHAINS; MEDICAL ASSISTANCE; MODELS, ECONOMIC; MUTATION; PROTEIN KINASE INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; UNCERTAINTY;

EID: 84872956655     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-39     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Felip E, Stahel RA, Pavlidis N. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2005, 16(Suppl 1):i28-i29.
3. William WN, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 2009, 136(3):701-709. 10.1378/chest.08-2968, 19318668.
4. Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R, Shepherd FA, De Petris L, et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the italian association of thoracic oncology. Lung Cancer 2010, 68(3):319-331. 10.1016/j.lungcan.2009.11.018, 20036027.
5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550. 10.1056/NEJMoa061884, 17167137.
6. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674):1525-1531. 10.1016/S0140-6736(09)60569-9, 19410716.
7. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(6):521-529. 10.1016/S1470-2045(10)70112-1, 20493771.
8. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012, 13(3):247-255. 10.1016/S1470-2045(12)70063-3, 22341744.
9. Zhang X, Zang J, Xu J, Bai C, Qin Y, Liu K, Wu C, Wu M, He Q, Zhang S, et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest 2011, 140(1):117-126. 10.1378/chest.10-2745, 21436247.
10. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440. 10.1016/S0140-6736(09)61497-5, 19767093.
11. Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012, 13(5):466-475. 10.1016/S1470-2045(12)70117-1, 22512843.
12. D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v116-v119.
13. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22(5):777-784. 10.1200/JCO.2004.08.001, 14990632.
14. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22(5):785-794. 10.1200/JCO.2004.07.215, 14990633.
15. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24(31):5034-5042. 10.1200/JCO.2006.06.3958, 17075123.
16. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139. 10.1056/NEJMoa040938, 15118073.
17. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372(9652):1809-1818. 10.1016/S0140-6736(08)61758-4, 19027483.
18. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993, 13(4):322-338. 10.1177/0272989X9301300409, 8246705.
19. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Value Health 2012, 15(6):812-820. 10.1016/j.jval.2012.06.014, 22999130.
20. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18(10):2095-2103.
21. Joerger M, Matter-Walstra K, Fruh M, Kuhnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2011, 22(3):567-574. 10.1093/annonc/mdq431, 20843984.
22. Matter-Walstra K, Joerger M, Kuhnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the swiss health care system. Value Health 2012, 15(1):65-71. 10.1016/j.jval.2011.08.1737, 22264973.
23. Carroll KJ. On the use and utility of the weibull model in the analysis of survival data. Control Clin Trials 2003, 24(6):682-701. 10.1016/S0197-2456(03)00072-2, 14662274.
24. Sahu SK, Dey DK, Aslanidou H, Sinha D. A Weibull regression model with gamma frailties for multivariate survival data. Lifetime Data Anal 1997, 3(2):123-137. 10.1023/A:1009605117713, 9384618.
25. Wilson DL. The analysis of survival (mortality) data: fitting Gompertz, Weibull, and logistic functions. Mech Ageing Dev 1994, 74(1-2):15-33.
26. NCCN Non-Small-Cell Lung Cancer Practice Guidelines: China Editions 2011, http://www.nccnchina.org/nccn-guidelines-china.aspx. Accessed May 28, 2012, NCCN Non-Small-Cell Lung Cancer Practice Guidelines: China Editions.
27. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98. 10.1056/NEJMoa011954, 11784875.
28. Liu B. Comparison of the cost of 4 kinds of second-line drug treatment regimes for Non-small cell lung cancer. China Pharmacy 2010, 21(26):2403-2406.
29. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008, 6:84. 10.1186/1477-7525-6-84, 2579282, 18939982.
30. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet 2011, 378(9804):1727-1740. 10.1016/S0140-6736(10)62101-0, 21565398.
31. List of Chinese administrative divisions by GDP per capita http://en.wikipedia.org/wiki/List_of_Chinese_administrative_divisions_by_GDP_per_capita. Accessed October 28, 2011, List of Chinese administrative divisions by GDP per capita.
32. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 2004, 7(5):518-528. 10.1111/j.1524-4733.2004.75003.x, 15367247.
33. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000, 9(3):235-251. 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O, 10790702.
34. Wu B, Chen H, Shen J, Ye M. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in china. Clin Ther 2011, 33(10):1446-1455. 10.1016/j.clinthera.2011.09.016, 21992806.
35. Klein R, Wielage R, Muehlenbein C, Liepa AM, Babineaux S, Lawson A, Schwartzberg L. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010, 5(8):1263-1272. 10.1097/JTO.0b013e3181e15d16, 20581708.
36. de Lima Lopes G, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 2012, 118(4):1032-1039. 10.1002/cncr.26372, 21792863.
37. Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, Dickson R, Ramani VS, Proudlove C. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 2010, 14(Suppl. 2):71-79.
38. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97(5):339-346. 10.1093/jnci/dji055, 15741570.
39. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967. 10.1056/NEJMoa0904554, 19692684.
40. Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007, 2(5):430-439. 10.1097/01.JTO.0000268677.87496.4c, 17473659.
41. Shin HR, Masuyer E, Ferlay J, Curado MP. Cancer in Asia - Incidence rates based on data in cancer incidence in five continents IX (1998-2002). Asian Pac J Cancer Prev 2010, 11(Suppl 2):11-16.